Lupin has launched Methylergonovine Maleate Tabs USP, 0.2 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Methylergonovine Maleate Tabs USP, 0.2 mg, had annual sales of approximately $71.5 million in the US (IQVIA MAT April 2018).
Lupin’s Methylergonovine Maleate Tabs USP, 0.2 mg, is the generic equivalent of Novartis Pharmaceuticals Corporation’s Methergine. It is indicated for the prevention and control of postpartum hemorrhage.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1912.70 |
| Dr. Reddys Labs. | 1364.40 |
| Cipla | 1460.60 |
| Zydus Lifesciences | 1171.25 |
| Lupin | 2515.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: